Low-risk endometrial carcinoma: is it time to subclassify it?

Objective: Endometrial cancer in Argentina represents the second most frequent gynecological cancer, accounting for 6% of all cases of cancer in women. The prognostic significance of lymphovascular space invasion (LVSI) and the patterns of tumor penetration in patients with FIGO Stage IA endometrial adenocarcinoma have not been established. The authors sought to determine if the pattern of tumor penetration and the LVSI status in patients with early-stage, low-risk endometrial cancer are correlated with recurrence and survival. Materials and Methods: The records of all women who underwent hysterectomies for the primary treatment of endometrial cancer from June 2010 to June 2015 at the Hospital Italiano de Buenos Aires were reviewed. Patients with Grade 1 or 2 endometrioid histology and FIGO Stage IA endometrial adenocarcinoma were analyzed. Fisher’s exact test and the Wilcoxon rank-sum test were used to compare patients with different types of tumor penetration [expansive or infiltrative/microcystic elongated and fragmented (MELF)] and different LVSI status. Recurrence-free survival (RFS) and overall survival (OS) were calculated using the Kaplan-Meier method. Results: Eighty-two (n = 82) patients met the inclusion criteria. Those patients without myometrial infiltration (M0) were excluded (n=72). Fourteen (17%) had LVSI. Fifty-one (62.19%) had an expansive type of penetration, 20 (24.39%) had an infiltrative type of penetration, and only 11 (13.41%) had a MELF type of penetration. The authors recorded six (7.31%) cases of recurrence after a mean followup period of 1,368 days (3.8 years). Five of those six cases had recurrences at the vaginal cuff, and one had recurrence in the peritoneum. It was possible to confirm a statistically significant relation between LVSI and the recurrence index. The incidence of recurrence in patients with LVSI was 35%, and in patients without LVSI, it was 0.7% (p < 0.000). No correlation between the type of tumor penetration and the incidence of recurrence was demonstrated in this study. Conclusion: Patients with low-risk endometrial cancer and LVSI have worse RFS and OS. No correlation between the type of tumor penetration and the incidence of recurrence was demonstrated in this study.

Endometrioid endometrial cancer; Lymphovascular space invasion; Pattern of tumor penetration; Recurrence; Survival.

[1] Estadísticas Vitales Información Básica – 2011 Secretaria de Políticas, Regulacion e Institutos, Direccio ́ n de Estadi ́ sticas e Informacio ́ ń de Salud ISSN 1668-9054 Serie 5 - Número 55.

[2] Pecorelli S.: “Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium”. Int. J. Gynecol. Obstet., 2009, 105, 103.

[3] Bokhman J.V.: “Two pathogenetic types of endometrial carcinoma”. Gynecol. Oncol., 1983, 15, 10.

[4] Euscher E. Fox P., Bassett R., Al-Ghawi H., Ali-Fehmi R., Barbuto D., et al.: “The pattern of myometrial invasion as a predictor of lymph node metastasis or extrauterine disease in low-grade endometrial carcinoma”. Am. J. Surg. Pathol., 2013, 37, 1728.

[5] dos Reis R., Burzawa J.K., Tsunoda A.T., Hosaka M., Frumovitz M., Westin S.N., et al.: “Lymphovascular Space Invasion Portends Poor Prognosis in Low-Risk Endometrial Cancer”. Int. J. Gynecol. Cancer, 2015, 25, 1292.

[6] O’Brien D.J., Flannelly G., Mooney E.E., Foley M.: “Lymphovascular space involvement in early stage well-differentiated endometrial cancer is associated with increased mortality”. BJOG, 2009, 116, 991.

[7] Euscher Fox P., Bassett R., Al-Ghawi H., Ali-Fehmi R., Barbuto D., Djordjevic B., et al.: “The pattern of myometrial invasion as a predictor of lymph node metastasis or extrauterine disease in low-grade endometrial carcinoma”. Am. J. Surg. Pathol., 2013, 37, 1728.

[8] Creasman W.T., Morrow C.P., Bundy B.N., Homesley H.D., Graham J.E., Heller P.B.: “Surgical pathologic spread patterns of endometrial cancer: A gynecologic oncology group study”. Cancer, 1987, 60, 2035.

[9] Schink J.C., Miller D.S., Lurain J.R., Rademaker A.W.: “Tumor size in endometrial cancer”. Cancer, 1991, 67, 2791.

[10] Mariani A., Webb M.J., Keeney G.L., Haddock M.G., Calori G., Podratz K.C.: “Low-risk corpus cancer: Is lymphadenectomy or radiotherapy necessary?” Am. J. Obstet. Gynecol., 2000, 182, 1506.

[11] Cox Bauer C.M., Greer D.M., Kram J.J.F., Kamelle S.A.: “Corrigendum to ‘Tumor diameter as a predictor of lymphatic dissemination in endometrioid endometrial cancer’” [Gynecol. Oncol. 141 (2016) 199–205]”. Gynecol. Oncol., 2017, 144, 649.

[12] Vaizoglu F., Yuce K., Salman M.C., Basaran D., Calis P., Ozgul N., Usubutun A.: “Lymphovascular space involvement is the sole independent predictor of lymph node metastasis in clinical early stage endometrial cancer”. Arch. Gynecol. Obstet., 2013, 288, 1391.

[13] Koskas M., Bassot K., Graesslin O., Aristizabal P., Barranger E., Clavel-Chapelon F., et al.: “Impact of lymphovascular space invasion on a nomogram for predicting lymph node metastasis in endometrial cancer”. Gynecol. Oncol., 2013, 129, 292..

[14] Morrow C.P, Bundy B.N., Kurman R.J., Creasman W.T., Heller P., Homesley H.D., Graham J.E.: “Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A gynecologic oncology group study”. Gynecol. Oncol., 1991, 40, 55.

[15] Weinberg L.E., Kunos C.A., Zanotti K.M.: “Lymphovascular space invasion (LVSI) is an isolated poor prognostic factor for recurrence and survival among women with intermediate- to high-risk earlystage endometrioid endometrial cancer”. Int. J. Gynecol. Cancer, 2013, 23, 1438.

[16] Alexander-Sefre F., Nibbs R., Rafferty T., Ayhan A., Singh N., Jacobs I.: “Clinical Value of Immunohistochemically Detected Lymphatic and Vascular Invasions in Clinically Staged Endometrioid Endometrial Cancer”. Int. J. Gynecol. Cancer, 2009, 19, 1074.

[17] Mittal K.R., Barwick K.W.: “Diffusely Infiltrating Adenocarcinoma of the Endometrium”. Am. J. Surg. Pathol., 1988, 12, 754.

[18] Lee K.R., Vacek P.M., Belinson J.L.: “Traditional and nontraditional histopathologic predictors of recurrence in uterine endometrioid adenocarcinoma”. Gynecol. Oncol., 1994, 54, 10.

[19] Murray S.K., Young R.H., Scully R.E. “Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcinoma: a study of their frequency, associated diagnostic problems, and prognostic significance”. Int. J. Gynecol. Pathol., 2003, 22, 324.

[20] Cole A.J., Quick C.M.: “Patterns of myoinvasion in endometrial adenocarcinoma: recognition and implications”. Adv. Anat. Pathol., 2013, 20, 141.

[21] Stewart C.J.R., Brennan B.A., Leung Y.C., Little L.: “MELF pattern invasion in endometrial carcinoma: association with low grade, myoinvasive endometrioid tumours, focal mucinous differentiation and vascular invasion”. Pathology, 2009, 41, 454.

[22] Stewart C.J.R., Little L.: “Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: evidence for epithelial-mesenchymal transition.” Histopathology, 2009, 55, 91.

[23] Quick C.M., May T., Horowitz N.S., Nucci M.R.: “Low-grade, lowstage endometrioid endometrial adenocarcinoma: a clinicopathologic analysis of 324 cases focusing on frequency and pattern of myoinvasion”. Int. J. Gynecol. Pathol., 2012, 31, 337.